(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.66%) $79.78
(1.43%) $2.33
(0.81%) $2 359.20
(0.83%) $28.60
(0.35%) $994.30
(0.07%) $0.928
(-0.10%) $10.85
(0.05%) $0.799
(0.17%) $92.70
-0.15% INR 33.30
Live Chart Being Loaded With Signals
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services...
Stats | |
---|---|
Volumen de hoy | 35 070.00 |
Volumen promedio | 1.31M |
Capitalización de mercado | 7.47B |
EPS | INR0 ( 2024-02-13 ) |
Próxima fecha de ganancias | ( INR0 ) 2024-05-27 |
Last Dividend | INR0.0500 ( 2020-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 97.94 |
ATR14 | INR0.120 (0.36%) |
Volumen Correlación
Nectar Lifesciences Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nectar Lifesciences Correlación - Moneda/Commodity
Nectar Lifesciences Finanzas
Annual | 2022 |
Ingresos: | INR15.24B |
Beneficio Bruto: | INR3.64B (23.91 %) |
EPS: | INR-1.080 |
FY | 2022 |
Ingresos: | INR15.24B |
Beneficio Bruto: | INR3.64B (23.91 %) |
EPS: | INR-1.080 |
FY | 2022 |
Ingresos: | INR16.69B |
Beneficio Bruto: | INR2.99B (17.94 %) |
EPS: | INR1.120 |
FY | 2021 |
Ingresos: | INR15.43B |
Beneficio Bruto: | INR2.58B (16.69 %) |
EPS: | INR-3.27 |
Financial Reports:
No articles found.
Nectar Lifesciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.100 | 2006-02-01 |
Last Dividend | INR0.0500 | 2020-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR1.900 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 1.38 | -- |
Div. Sustainability Score | 1.879 | |
Div.Growth Potential Score | 2.80 | |
Div. Directional Score | 2.34 | -- |
Year | Amount | Yield |
---|---|---|
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.0500 | 0.19% |
2019 | INR0.0500 | 0.24% |
2020 | INR0.100 | 0.81% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SYNGENE.NS | Dividend Junior | 2023-06-30 | Sporadic | 9 | 0.05% | |
NEOGEN.NS | Dividend Junior | 2023-08-25 | Annually | 6 | 0.18% | |
ICIL.NS | Dividend Junior | 2023-08-11 | Annually | 10 | 0.77% | |
CENTURYPLY.NS | Dividend Junior | 2023-09-20 | Annually | 19 | 0.20% | |
SAFARI.NS | Dividend Junior | 2023-07-13 | Semi-Annually | 3 | 0.08% | |
LOTUSEYE.NS | Dividend Junior | 2023-09-18 | Sporadic | 8 | 0.55% | |
GENCON.NS | Dividend Junior | 2023-09-22 | Annually | 4 | 0.08% | |
ARROWGREEN.NS | Dividend Junior | 2023-09-20 | Annually | 10 | 0.15% | |
THERMAX.NS | Dividend Junior | 2023-07-20 | Annually | 23 | 0.38% | |
ORIENTELEC.NS | Dividend Junior | 2023-07-26 | Semi-Annually | 7 | 0.41% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00493 | 1.500 | 9.90 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.00754 | 1.500 | -1.027 | -1.541 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.093 | 1.000 | -0.706 | -0.706 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.43 | 2.00 | 8.19 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.43 | 2.00 | 7.29 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.251 | 1.000 | 9.14 | 9.14 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0553 | 1.000 | -0.893 | -0.893 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.879 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 96.93 | 1.000 | 0.310 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00754 | 2.50 | -0.660 | -1.541 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.43 | 2.00 | 8.19 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.43 | 2.00 | 8.19 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.722 | 1.500 | 8.52 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0746 | 1.000 | -0.635 | 0 | [0.1 - 0.5] |
Total Score | 2.80 |
Nectar Lifesciences
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico